Second-line chemotherapy in advanced and metastatic CRC
Authors:
- Marta Roqué i FigulsMFMarta Roqué i Figuls
- Ivan SolàISIvan Solà
- Marta Martin-RichardMMMarta Martin-Richard
- Juan-José LópezJLJuan-José López
- Xavier Bonfill CospXCXavier Bonfill Cosp
- 15 April 2009
- reference entry
- Published by Wiley
- No. 2,p. CD006875
Abstract
Chemotherapy is widely used in colorectal cancer that has relapsed or failed to respond to first-line treatment. To determine the efficacy of second-line chemotherapy for the treatment of advanced colorectal cancer. We performed electronic searches in the following databases: MEDLINE (via PubMed; 1964-September 2007), EMBASE (via OVID; 1980-September 2007) and The Cochrane Library 2007, Issue 2. Studies assessing the efficacy of second-line chemotherapy (single or combined treatment with any chemotherapeutic agent, at any dose and number of cycles) in patients with advanced colorectal cancer that progressed, recurred or did not respond to first-line chemotherapy. A descriptive analysis of the included trials was performed, due to the huge clinical heterogeneity between them. Seven randomized controlled trials (RCTs) were included; one of high quality, five of moderate quality, and one conference Second-line chemotherapy (irinotecan) showed moderate benefits in overall survival and progression-free survival over Best Supportive Care (BSC) and fluorouracil (5-FU). Fractionated administration has not proven to be more beneficial and is more toxic. Definitive results concerning the benefits and risks of oxaliplatin are pending publication. Second-line chemotherapy is effective in prolonging time to progression and survival in patients with advanced colorectal cancer. Further RCTs are needed to assess the optimal chemotherapy regimen.Keywords
This publication has 30 references indexed in Scilit:
- Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapyBritish Journal of Cancer, 2004
- A Randomized Trial Comparing Defined-Duration With Continuous Irinotecan Until Disease Progression in Fluoropyrimidine and Thymidylate Synthase Inhibitor—Resistant Advanced Colorectal CancerJournal of Clinical Oncology, 2004
- Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized studyCancer Chemotherapy and Pharmacology, 2003
- Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III TrialJournal of Clinical Oncology, 2003
- Phase III Comparison of Two Irinotecan Dosing Regimens in Second-Line Therapy of Metastatic Colorectal CancerJournal of Clinical Oncology, 2003
- Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase II–III randomized trialAnnals of Oncology, 2000
- Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancerAnnals of Oncology, 2000
- Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapyCritical Reviews in Oncology/Hematology, 1999
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerThe Lancet, 1998
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998